El-Rifaie, A., Rashed, L., Abd Alla, A., Zaki, D. (2022). Tissue Expression of Visfatin in Psoriatic Patients. test, 3(4), 46-56. doi: 10.21608/ejmr.2022.264950
Abd El-Aziz El-Rifaie; Laila Ahmed Rashed; Ahlam Hosny Abd Alla; Doaa Gamal Zaki. "Tissue Expression of Visfatin in Psoriatic Patients". test, 3, 4, 2022, 46-56. doi: 10.21608/ejmr.2022.264950
El-Rifaie, A., Rashed, L., Abd Alla, A., Zaki, D. (2022). 'Tissue Expression of Visfatin in Psoriatic Patients', test, 3(4), pp. 46-56. doi: 10.21608/ejmr.2022.264950
El-Rifaie, A., Rashed, L., Abd Alla, A., Zaki, D. Tissue Expression of Visfatin in Psoriatic Patients. test, 2022; 3(4): 46-56. doi: 10.21608/ejmr.2022.264950

Tissue Expression of Visfatin in Psoriatic Patients

Egyptian Journal of Medical Research
Volume 3, Issue 4, October 2022, Pages 46-56    PDF (595.12 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.264950
Authors
Abd El-Aziz El-Rifaie1; Laila Ahmed Rashed2; Ahlam Hosny Abd Alla1; Doaa Gamal Zaki1
1Dermatology department, Faculty of Medicine, Beni-Suef University, Egypt
2Dermatology department, Faculty of Medicine, Cairo University, Egypt
Abstract
Background: Psoriasis is a chronic disease, in which genetic, immunological, and environmental factors play a significant role. The immunological mechanism involved in pathogenesis causes cutaneous inflammation and keratinocytes hyperproliferation. Subcutaeous adipose tissue secretes adipokines which play a role in cutaneous inflammation. Visfatin is an adipokine that induces inflammatory process by increasing cytokines production and activation. It affects inflammatory and immune response through induction of chemotaxis. Aim of this work: To estimate visfatin level in lesional tissues of psoriatic patients in comparison with healthy controls and its correlation with disease severity. Patients and Methods: The expression of visfatin was detected in the skin of 30 psoriasis patients and 30 healthy controls using using ELISA technique. Results: Visfatin expression was significantly higher in psoriasis patients compared to healthy controls. In addition, there was no significant difference between visfatin expression and severity of the disease.  Conclusion: Visfatin may play a role in pathogenesis of psoriasis.
Keywords
Psoriasis; Visfatin; expression
References
  1. Langley, R. G. B., Krueger, G. G. & Griffiths, C. E. M. (2005):-Psoriasis: epidemiology, clinical features, and quality of life. Annals of the rheumatic diseases, 64(suppl 2), ii18-ii23.
  2. Griffiths, C.E. & Barker, J.N.      (2007):- Pathogenesis and clinical features of psoriasis. The Lancet, 370(9583), 263-271.
  3. Schons, K.R.R., Knob, C.F., Murussi, N., Beber, A.A.C., Neumaier, W. & Monticielo, O.A. (2014):- Nail psoriasis; a review of the liter ature. Anais brasileiros de dermatologia, 89(2), 312-317.
  4. Krueger, J.G., & Bowcock, A. (2005):- Psoriasis pathophysiology; current concepts of pathogenesis. Annals of the rheumatic diseases, 64(suppl 2), ii30-ii36.
  5. Bai, F., Zheng, W., Dong, Y., Wang, J., Garstka, M. A., Li , R. & Ma, H. (2018):- Serum levels of adipokines and cytokines in psoriasis patients; a systematic review and meta-analysis. Oncotarget, 9 (1), 1266.
  6. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K. & Watanabe, E. (2005):- Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307(5708), 426-430.
  7. Moschen, A. R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H. & Tilg, H. (2007):- Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology, 178(3), 1748-1758.
  8. Stofkova, A. (2010):- Resistin and visfatin; regulators of insulin sensitivity, inflammation and immunity. Endocrine regulations, 44 (1), 25-36.
  9. Okan, G., Baki, A. M., Yorulmaz, E., Dogru‐Abbasoglu, S. & Vural, P. (2016):- Serum visfatin, fetuin‐A, and pentraxin 3 levels in patients with psoriasis and their relation to disease severity. Journal of clinical laboratory analysis, 30(4), 284-289.
  10. Christophers, E. (2007):- Comorbidities in psoriasis. Clinic s in dermatology, 25(6), 529-534.‏
  11. Verghese B, Bhatnagar S, Tanwar R, Bhattacharjee J (2011):- Serum cytokine profile in psoriasis-a case-control study in a tertiary care hospital from northern India. Indian J Clin Biochem; 26(4): 373-377.
  12. Antuna-Puente, B., Feve, B., Fellahi, S. & Bastard, J. P. (2008):- Adipokines; the missing link between insulin resistance and obesity. Diabetes & metabolism, 34(1), 2-11.
  13. Ala-Houhala MJ, Karppinen T, Vahavihu K, et al. (2014):- Narrow-band Ultraviolet B Treatment Boosts Serum 25-hydroxy vitamin D in Patients with Psoriasis on Oral Vitamin D Supplementation. Acta Derm Venereol; 94: 146–151.
  14. Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M. R. & Bluher, M. (2005):- Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes, 54(10), 2911-2916.‏
  15. Friebe, D., Neef, M., Kratzsch, J., Erbs, S., Dittrich, K., Garten, A. & Bluher, M. (2011):- Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase(NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia, 54(5), 1200-1211.‏
  16. Komine, M., Karakawa, M., Takekoshi, T., Sakurai, N., Minatani, Y., Mitsui, H. & Tamaki, K. (2007):- Early inflammatory changes in the “perilesional skin” of psoriatic plaques: is there interaction between dendritic cells and keratinocytes? Journal of investigative dermatology, 127(8), 1915-1922.‏
  17. Parisi, R., Symmons, D. P., Griffiths, C. E. & Ashcroft, D. M. (2013):- Global epidemiology of psoriasis; a systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377-385.
  18. Ismail, S. A. & Mohamed, S. A. (2012):- Serum levels of visfatin and omentin‐1 in patients with psoriasis and their relation to disease severity. British Journal of Dermatology, 167(2), 436-439.           
  19. Lopez‐Estebaranz, J. L., Sanchez‐Carazo, J. L. & Sulleiro, S. (2016):- Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study. The Journal of dermatology, 43(4), 395-401.
  20. Abd-ElRaheem, T., Ali, S. A., Mohamed, S. R. & Mohamed, H. A. (2019):- Visfatin, Omentin-1 and lipid profile in patients with psoriasis their relation and Disease to severity. Fayoum University Medical Journal, 2(1), 32-36.
  21. Badran, F. K., Genedy, R. M., Swelem, R. S. & Al-Rawi, M. Z. (2014):- Evaluation of serum level of visfatin among psoriatic patients. Egyptian Journal of Dermatology and Venerology, 34(2), 107.
  22. Yan, W., Huang, Y., Yan, X. & Zhou, Y. (2011):- Clinical significance of serum visfatin and high mobility groupbox1 (HMGB1) in psoriasis vulgaris. Chinese J. Clin, 5, 9-15.‏
  23. Sereflican, B., Goksugur, N., Bugdayci, G., Polat, M. & Haydar Parlak, A. (2016):- Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-α) levels in patients with psoriasis and their correlation with disease severity. Acta Dermatovenerologica Croatica, 24(1), 13-13.‏
  24. Bozkurt, N. M., Yildirim, M., Ceyhan, A. M., Kara, Y. & Vural, H. (2010):- Psoriasisli hastalarda serum visfatin duzeylerinin arastirilmasi. TURKDERM-Deri Hastaliklari ve Frengi Arsivi, 44(1), 15-18.‏
  25. Chyl-Surdacka, K. M., Bartosinska, J., Kowal, M., Przepiorka-Kosinska, J., Krasowska, D. & Chodorowska, G. (2020):- Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities. Advances in Clinical and Experimental Medicine, 29(1), 79-84.‏
  26. Abd Elfattah, W. M. (2017):- Serum level of Visfatin in Psoriasis and its Relation to Disease Severity. The Egyptian Journal of Hospital Medicine, 69(1), 1558-1562.‏
Statistics
Article View: 213
PDF Download: 170